Phase III Daclatasvir, Sofosbuvir, and Ribavirin in Cirrhotic Participants and Participants Post-liver Transplant

For more information regarding BMS clinical trial participation, please visit
www.BMSStudyConnect.com

Inclusion Criteria:

- Participants must be able to understand and agree to comply with the prescribed
dosing regimens and procedures, report for regularly scheduled study visits, and
reliably communicate with study personnel about adverse events and concomitant
medications

- Participants chronically infected with hepatitis C virus (HCV) Genotype 1, 2, 3, 4,
5, or 6 with HCV RNA viral load of ≥10,000 IU/mL at screening

- Participants may be treatment-naïve or treatment-experienced

- Cirrhotic participants must have cirrhosis confirmed by biopsy, Fibroscan or
fibrotest and Aspartate aminotransferase platelet ratio index (APRI) criteria as
outlined in the protocol

- Post-transplant participants must be at least 3 months post-transplant with no
evidence of moderate or severe rejection

Exclusion Criteria:

- History of multi-organ transplant, with the exception of dual transplantation of the
liver/kidney, is prohibited

- Current or known history of cancer (with the following exceptions: In situ carcinoma
of the cervix, adequately treated basal or squamous cell carcinoma of the skin, or
hepatocellular carcinoma within Milan criteria for transplantation) within 5 years
prior to screening

- Evidence of an ongoing medical condition contributing to chronic liver disease other
than HCV (such as, but not limited to: hemochromatosis, autoimmune hepatitis,
metabolic liver disease, alcoholic liver disease, or toxin exposures)

- History of HIV infection or chronic hepatitis B virus (HBV) as documented by HBV
serologies (e.g., HBsAg-seropositive). Participants with resolved HBV infection may
participate (e.g., HBcAb-seropositive with concurrent HBsAg-seronegative)

- Active hospitalization for decompensated liver disease